ArticleEuropean radiology2026
Clinical and MRI characteristics of germline pathogenic variant carriers diagnosed with prostate cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCompare the clinical and imaging features of prostate cancer (PCa) patients harboring a germline pathogenic variant (PV) to sporadic controls. MATERIALS AND
methodsA single-center retrospective case-control study was performed by identifying patients with positive germline genetic testing for a PV diagnosed with prostate cancer between December 2015 and October 2025. Clinical, pathologic, and MRI characteristics of PV carriers were compared to a control group of consecutive patients diagnosed with PCa over 1 year. Mann-Whitney U-test was used for continuous data and Fisher's exact test for categorical comparisons.
resultsA total of 62 patients with PCa harboring ≥ 1 PV and an MRI at diagnosis were compared to 246 controls. The most frequent genes were Lynch syndrome (LS) associated (17.7%), CHEK2 (21.0%), ATM (17.7%), and BRCA2 (19.4%). Median age of PV carriers was not significantly younger than controls at diagnosis (65 years [IQR, 58-71], vs 67 years [61-73], p = 0.05). The proportion of patients with a positive MRI (PI-RADS ≥ 3) did not differ between groups (98% PV vs 96% control, p = 0.70). PV carriers were more likely to receive a PI-RADS 5 score (OR: 2.7; CI: 1.5-4.9, p < 0.01) and grade 3 extra-prostatic extension (OR: 3.0; CI: 1.5-5.8, p < 0.01). At prostatectomy, the proportion of patients reclassified to a higher-grade group was larger for PV carriers (37% vs 20%, p = 0.046).
conclusionPV carriers with PCa tend to manifest more aggressive imaging findings and are more likely to experience pathologic upgrading at prostatectomy. KEY POINTS: Question Differences in the clinical and imaging characteristics of sporadic prostate cancer (PCa) patients compared to patients harboring a PCa-associated germline pathogenic variant remain understudied. Findings PV carriers with PCa manifest more aggressive imaging features and are more likely to demonstrate pathologic upgrading at prostatectomy. Clinical relevance Knowledge of the unique clinical and imaging manifestations of hereditary PCa should support ongoing early detection studies and underscore the need for radiologists to be familiar with patient-centered early detection strategies utilizing MRI.
Indexed as
Identifiers
42806037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.